Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer

PURPOSE: Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients. MATERIALS AND METHODS: We evaluated patients who received ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Kim, Tae Won, Kim, Kyu-pyo, Kim, Tae-You, Han, Sae-Won, Lee, Ji Yun, Lim, Sung Hee, Lee, Min-Young, Kim, Haesu, Park, Young Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614225/
https://www.ncbi.nlm.nih.gov/pubmed/25672574
http://dx.doi.org/10.4143/crt.2014.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614225/
https://www.ncbi.nlm.nih.gov/pubmed/25672574
http://dx.doi.org/10.4143/crt.2014.126

Ejemplares similares